PDS Biotechnology (PDSB) Price & Analysis

Compare

807 Followers

PDSB Stock Chart & Stats

$0.67

-$0.09(-5.36%)

At close: Jan 08 4:00 PM EST

$0.67

-$0.09(-5.36%)

Day’s Range― - ―

52-Week Range$0.60 - $1.92

Previous CloseN/A

Volume197.50K

Average Volume (3M)596.35K

Market Cap

$36.50M

Enterprise Value$30.07M

Total Cash (Recent Filing)$26.20M

Total Debt (Recent Filing)$17.97M

Price to Earnings (P/E)―

Beta2.49

Next Earnings

Mar 26, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding54,721,306

10 Day Avg. Volume406,028

30 Day Avg. Volume596,350

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)3.13

Price to Sales (P/S)0.00

P/FCF Ratio-1.69

Enterprise Value/Market Cap0.82

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.99K

Enterprise Value/Ebitda-0.98

Forecast

1Y Price Target

$15.00

Price Target Upside2138.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.67

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Accelerated Approval PathwayPrioritizing progression-free survival positions the program for a potential accelerated approval route by matching the trial endpoint to faster-accumulating clinical events.

Regulatory AlignmentFDA agreement to amend the VERSATILE-003 protocol to use progression-free survival as an interim primary endpoint removes a regulatory overhang and clarifies a key approval milestone tied to interim data.

Trial Costs And Cash BurnChanging the interim endpoint to progression-free survival should shorten trial timelines and reduce operational expenses and cash burn because progression events accrue faster than death events.

Bears Say

Approval Dependency On Overall SurvivalFull traditional approval remains contingent on demonstrating a median overall survival benefit, requiring the company to generate longer-term survival data before full market authorization.

Commercial And Reimbursement UncertaintyRelying on an accelerated approval based on progression-free survival could leave pricing, reimbursement and broad clinical adoption uncertain until confirmatory overall survival data are produced.

Endpoint Translation RiskA strong progression-free survival signal may not translate into an overall survival benefit, creating the risk that accelerated approval might not convert to full approval.

PDS Biotechnology News

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/4/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.021% in...

19h ago

IPI

VOO vs. VTI: Which Vanguard ETF Is the Smarter Buy for 2026?

Vanguard S&P 500 ETF ($VOO) and Vanguard Total Stock Market ETF ($VTI) are both core Vanguard ETFs, but...

21h ago

NOW

SPX

Why Is the VTI ETF Down Today? Daily Snapshot – 3/3/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, was down 1.42% in...

2d ago

MSS

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/2/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.82% in...

3d ago

IPI

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/27/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 1.01% in...

6d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/26/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.11% in...

7d ago

CLB

PDS announces adoption of protocol amendment to Phase 3 VERSATILE-003 trial

PDS Biotechnology (PDSB) announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The...

13d ago

PDSB

PDS Biotechnology Highlights PDS0101 Data in Updated Presentation

The latest update is out from PDS Biotechnology ( ($PDSB) ). On February 23, 2026, PDS Biotechnology updated...

9d ago

PDSB

PDS Biotechnology Updates VERSATILE-003 Trial for Accelerated Approval

PDS Biotechnology ( ($PDSB) ) has issued an announcement. On February 20, 2026, PDS Biotechnology adopted an amended...

13d ago

PDSB

PDS Biotechnology Highlights Promising Phase 2 Prostate Cancer Data

PDS Biotechnology ( ($PDSB) ) has issued an announcement. On January 28, 2026, PDS Biotechnology announced that the...

1M ago

PDSB

PDS announces presentation of preliminary Phase 2 results on PDS01ADC

PDS Biotechnology (PDSB) announced that results of a National Cancer Institute-led study of the Company’s investigational Interleukin-12 tumor...

1M ago

PDSB

PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection

PDS Biotechnology ( ($PDSB) ) has shared an announcement. On January 22, 2026, PDS Biotechnology announced that the...

1M ago

PDSB

PDS Biotechnology announces new U.S. patent covering tech underlying PDS0101

PDS Biotechnology (PDSB) announced that the U.S. Patent Office has issued a Notice of Allowance for the Company’s...

1M ago

PDSB

PDS Biotechnology announces FDA alignment on use of PFS as primary endpoint

PDS Biotechnology (PDSB) announced that the Company has submitted a protocol amendment to the U.S. FDA for its...

2M ago

PDSB

PDSB FAQ

What was PDS Biotechnology Corporation’s price range in the past 12 months?

PDS Biotechnology Corporation lowest stock price was $0.60 and its highest was $1.92 in the past 12 months.

What is PDS Biotechnology Corporation’s market cap?

PDS Biotechnology Corporation’s market cap is $36.50M.

When is PDS Biotechnology Corporation’s upcoming earnings report date?

PDS Biotechnology Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.

How were PDS Biotechnology Corporation’s earnings last quarter?

PDS Biotechnology Corporation released its earnings results on Nov 13, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.197 by $0.007.

Is PDS Biotechnology Corporation overvalued?

According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PDS Biotechnology Corporation pay dividends?

PDS Biotechnology Corporation does not currently pay dividends.

What is PDS Biotechnology Corporation’s EPS estimate?

PDS Biotechnology Corporation’s EPS estimate is -0.2.

How many shares outstanding does PDS Biotechnology Corporation have?

PDS Biotechnology Corporation has 54,721,306 shares outstanding.

What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?

PDS Biotechnology Corporation reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.197. Following the earnings report the stock price went down -12.253%.

Which hedge fund is a major shareholder of PDS Biotechnology Corporation?

Currently, no hedge funds are holding shares in PDSB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

PDS Biotechnology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-221.81%

Trailing 12-Months

Asset Growth

-33.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

PDS Biotechnology (PDSB) Earnings & Revenues

Historic Earnings Reports

PDSB Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presents a balanced view with significant achievements in clinical trial progress and strategic amendments to enhance regulatory approval processes. However, financial challenges and a temporary trial pause highlight ongoing operational and funding hurdles.View all PDSB earnings summaries

PDSB Stock 12 Month Forecast

Average Price Target

$15.00

▲(2138.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","-1":"-$1","3.25":"$3.25","7.5":"$7.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.25,7.5,11.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.826,1.9163076923076923,3.0066153846153845,4.096923076923076,5.187230769230768,6.277538461538461,7.367846153846153,8.458153846153845,9.548461538461538,10.638769230769231,11.729076923076923,12.819384615384614,13.909692307692307,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.826,1.9163076923076923,3.0066153846153845,4.096923076923076,5.187230769230768,6.277538461538461,7.367846153846153,8.458153846153845,9.548461538461538,10.638769230769231,11.729076923076923,12.819384615384614,13.909692307692307,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.826,1.9163076923076923,3.0066153846153845,4.096923076923076,5.187230769230768,6.277538461538461,7.367846153846153,8.458153846153845,9.548461538461538,10.638769230769231,11.729076923076923,12.819384615384614,13.909692307692307,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.63,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.935,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.717,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.769,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.826,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >